Does Canopy Growth Corp. Have Long-Term Potential?

Canopy Growth Corp. (TSX:WEED) has come down from the highs of last year, but is the company still a feasible long-term investment?

| More on:

Late last year, as talk of legalizing marijuana for recreational use began to gain traction, stocks such as Canopy Growth Corp. (TSX:WEED) began to take off. At that time, Canopy surged to new highs and was lifted further through a series of acquisitions that were announced shortly thereafter, first for a distributor in Germany and then for another competitor in Canada.

Since then, the stock has stopped its meteoric rise, which was arguably inflated. The stock is still up an incredible 160% over the past 12-month period, despite being down nearly 9% year to date. This has some investors questioning if the bubble (if there was one) around Canopy has finally popped and if Canopy is a great investment.

A great market opportunity exists

As per Health Canada, nearly 130,000 Canadians are eligible to purchase marijuana for medicinal purposes, and that number is set to grow by leaps and bounds over the next few years from both domestic and foreign pressures.

While Canada aims to have legislation in place to legalize recreational use marijuana by next summer, the early draft submitted this past spring left many gaps to be filled before the bill becomes law, and the provinces still have to weigh in with their own legislation.

On the international stage, some countries are beginning to open to both medicinal and recreational use, but the process is slow. That’s not to say that companies aren’t already capitalizing on the opportunity that is unfolding, which is huge.

By way of example, Canopy acquired the Germany-based distributor MedCann late last year. Growing and harvesting cannabis in Germany is still illegal, meaning medicinal products need to be imported. Canopy is already recognized as the leading supply source that is legally available from North America, which MedCann can now distribute to customers in that market.

Additionally, an increasing amount of research is now looking at the use of cannabis for treatments in a variety of conditions, ranging from chronic pains to cancer treatments. With results looking promising, demand for cannabis is only set to grow over the next few years.

Should you invest in cannabis stocks?

Investors that have made the jump and purchased marijuana stock have likened the opportunity that is unfolding to investing in liquor companies towards the end of prohibition. While there are some parallels to this analogy, and there is a significant upside to be made over the long term, that long-term time frame could be some time out.

There’s also the question of profitability, which skeptics will point to when looking at companies like Canopy. Canopy’s $0.14-per-share loss would be enough to have investors running if it were any other established industry, but this is where those skeptics are not looking at the position that Canopy and, by extension, the whole market is in.

In terms of full results, Canopy brought in $14.7 million in revenue for the quarter, which was a 50% increase over the same quarter last year, so that loss is not as dire as it would seem. If anything, Canopy is pursuing aggressive growth, which is exactly what the company should be doing.

The cannabis market is still very much in its infancy, and for any company to excel at this point, the focus should be on expansion. Canopy has cornered 50% of the market in Canada and is working on expanding both in Canada and abroad. As economies of scale start to set in, and the market expands, the profitability that skeptics are concerned about will come in time.

Until then, Canopy remains an intriguing opportunity for investors looking at long-term growth that have a higher tolerance for risk.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Demetris Afxentiou has no position in any stocks mentioned.

More on Investing

stock analysis
Investing

“GARP” Investing: 3 Can’t-Miss Stocks to Buy Now

goeasy (TSX:GSY) and other low-cost growth stocks could make your portfolio a market beater over the long run!

Read more »

calculate and analyze stock
Investing

My Take: The Best TSX Stock to Buy With $1,000 in March 2024

Here's why Restaurant Brands (TSX:QSR) remains a top TSX stock long-term investors should buy right now.

Read more »

Woman has an idea
Tech Stocks

Prediction: 1 Stock That Could Trounce the Market 

The TSX has been favouring tech stocks, but not this one. However, it has the potential to trounce the market…

Read more »

Dividend Stocks

The Top Canadian REITs to Buy in April 2024

For growth and dividends this April, look to these two REITs that have quite the promising present as well as…

Read more »

Canadian Dollars
Stock Market

Where to Invest $5,000 in April 2024

Do you have some extra cash to spare? Here are five companies to invest $5,000 in next month.

Read more »

Plane on runway, aircraft
Stocks for Beginners

Up 53% From its 52-Week Low, Is Cargojet Stock Still a Buy?

Cargojet (TSX:CJT) stock is up a whopping 53%, nearing closer to 52-week highs from 52-week lows, so what's next for…

Read more »

Question marks in a pile
Bank Stocks

Should You Buy Canadian Western Bank for its 4.8% Dividend Yield?

Down 35% from all-time highs, Canadian Western Bank offers a tasty dividend yield of 4.8%. Is the TSX bank stock…

Read more »

Gold bars
Metals and Mining Stocks

Why Alamos Gold Jumped 7% on Wednesday

Alamos (TSX:AGI) stock and Argonaut Gold (TSX:AR) surged after the companies announced a friendly acquisition for $325 million.

Read more »